RBC Capital Maintains Outperform on Viridian Therapeutics, Lowers Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has maintained an 'Outperform' rating on Viridian Therapeutics (NASDAQ:VRDN), but lowered the price target from $44 to $35.

October 31, 2023 | 2:32 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
RBC Capital has maintained an 'Outperform' rating on Viridian Therapeutics, but lowered the price target from $44 to $35.
The news is directly related to Viridian Therapeutics and is likely to influence investor sentiment. While the 'Outperform' rating is maintained, the lowering of the price target may create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100